Highlights XBiotech Inc.

Equities

XBIT

CA98400H1029

Market Closed - Nasdaq Other stock markets 01:30:00 18/05/2024 am IST			5-day change	1st Jan Change
8.43 ^USD	-1.75%		+1.44%	+110.75%

15/03	XBiotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04/01	XBiotech Inc. to Begin Constructing New R&D Facility on Its 48-Acre Campus	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

XBiotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16/03	CI
XBiotech Inc. to Begin Constructing New R&D Facility on Its 48-Acre Campus	04/01	CI
XBiotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Xbiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, A Novel Candidate Therapy for Stroke	26/23/26	CI
Xbiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer	30/23/30	CI
XBiotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Tranche Update on XBiotech Inc.'s Equity Buyback Plan announced on May 17, 2023.	20/23/20	CI
XBiotech Inc.'s Equity Buyback announced on May 17, 2023, has expired with 3,561 shares, representing 0.01% for $0.01 million.	15/23/15	CI
XBiotech Inc. announces an Equity Buyback for $80 million worth of its shares.	17/23/17	CI
XBiotech Inc. authorizes a Buyback Plan.	17/23/17	CI
XBiotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
XBiotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/22/10	CI
XBiotech Inc. Announces First Patient Enrolled into the French National Cancer Institute Sponsored Phase I/Ii/Iii Clinical Study for Natrunix™ Therapy for Colorectal Cancer	13/22/13	CI
XBiotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	10/22/10	CI
XBiotech Announces Successful Completion of Phase I Portion of Pancreatic Cancer Study	20/22/20	CI
XBiotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	11/22/11	CI
XBiotech Says French Regulator Approves Trial of Natrunix Combination Treatment for Colorectal Cancer; Shares Rise	28/22/28	MT
French National Agency for the Safety of Medicines and Health Products Approves the Launch of Multicenter Randomized Clinical Study for Xbiotech’s Candidate Cancer Treatment Natrunix in Combination with Trifluridine/Tipiracil for the Treatment of Colorectal Cancer	28/22/28	CI
XBiotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	16/22/16	CI
Johnson & Johnson to Record $610 Million Impairment Charge in Q1 From Terminating Development of Atopic Dermatitis Drug	03/22/03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights XBiotech Inc.

Equities

XBIT

CA98400H1029

Highlights

Filters